Avid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics’ ZYNLONTA™ (Loncastuximab Tesirine-Lpyl)
25 mai 2021 08h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting
19 mai 2021 17h05 HE
|
MacroGenics, Inc.
Dose escalation: anti-tumor activity observed in melanoma (including one confirmed partial response) and in mCRPC patientsCohort expansion in mCRPC: 11/22 (50%) patients have ≥ 50% PSA reduction;...
MacroGenics Announces Presentations at the 2021 AACR Annual Meeting
10 avr. 2021 08h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, April 10, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
Sorrento Announces First Patient Treated in Phase IB AL Amyloidosis Trial with STI-6129, an Anti-CD38 Antibody-Drug Conjugate
18 mars 2021 09h00 HE
|
Sorrento Therapeutics, Inc.
STI-6129 is an antibody-drug conjugate (ADC) composed of a fully human monoclonal anti-CD38 antibody covalently bound by a proprietary chemical linker to a duostatin tubulin inhibitor.Amyloid Light...
Growing at an annualized rate of over 12%, the ADC contract manufacturing market is estimated to reach close to USD 3 Billion by 2030, claims Roots Analysis
04 févr. 2021 11h00 HE
|
Roots Analysis
London, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “ADC Contract Manufacturing Market (4th Edition), 2020-2030” report to its list of offerings. Manufacturing of...
Kemp Wins IT Optimisation Product of the Year
13 oct. 2020 09h00 HE
|
Kemp
NEW YORK, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Kemp, the leader in powering always-on application experience [AX], today announced it has won “IT Optimisation Product of the Year” as part of the annual...
MacroGenics Announces MGC018 Publication in Molecular Cancer Therapeutics
23 sept. 2020 07h15 HE
|
MacroGenics, Inc.
Manuscript describes preclinical development of MGC018Phase 1 dose expansion trial evaluating MGC018 in patients with mCRPC, TNBC and NSCLC is currently recruiting patients ROCKVILLE, MD,...
Software Load Balancers Secure First Responder Electronic Patient Care Reporting
27 août 2020 09h00 HE
|
Kemp
ImageTrend taps Kemp for healthcare compliance while keeping on-scene patient data flowing during COVID-19 and beyond NEW YORK, Aug. 27, 2020 (GLOBE NEWSWIRE) -- When it comes to electronic patient...
Kemp Optimizes Application Experience for Citrix Virtual Apps and Desktops
22 juil. 2020 09h00 HE
|
Kemp
NEW YORK, July 22, 2020 (GLOBE NEWSWIRE) -- Kemp, the leader in powering always-on application experience [AX], today announced that its LoadMaster load balancers now provide templated, turn-key...
Cybrexa Therapeutics Completes Successful Pre-IND Meeting With FDA for CBX-12 (alphalex™-exatecan), a Novel Treatment for Solid Tumors
07 juil. 2020 07h00 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., July 07, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...